<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05089591</url>
  </required_header>
  <id_info>
    <org_study_id>IPL</org_study_id>
    <nct_id>NCT05089591</nct_id>
  </id_info>
  <brief_title>Intense Pulsed Light in Meibomian Gland Dysfunction</brief_title>
  <official_title>Efficacy of Intense Pulsed Light Treatment in Patients With Meibomian Gland Dysfunction</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Prim. Prof. Dr. Oliver Findl, MBA</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Vienna Institute for Research in Ocular Surgery</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Meibomian gland dysfunction (MGD) is a major cause of dry eye disease (DED). Up to 86% of&#xD;
      patients suffering from DED also show signs of MGD. Traditional treatment of MGD is based on&#xD;
      eye lid hygiene and massage in combination with intensive usage of lubricants.&#xD;
&#xD;
      Recently, a novel technology the intense pulsed light (IPL) therapy was introduced, which&#xD;
      shows promising results in patients with meibomian gland dysfunction. Originating from field&#xD;
      of dermatology, subjecting improvement of dry eye symptoms was recognized after the treatment&#xD;
      of facial rosacea using IPL. Different hypotheses exist how IPL treatment might improve the&#xD;
      situation in the dry eye patient. Warming of the eyelid, due to the light application and&#xD;
      reduction of bacterial load are two possible mode of actions. Further, the used wavelengths&#xD;
      in IPL may be modified that the light is only absorbed by oxygenated haemoglobin, which lead&#xD;
      to an obliteration of telangiectasia and reduced inflammation on the lid margin. This&#xD;
      principal is applied in the treatment of facial rosacea.&#xD;
&#xD;
      Aim of this study is to investigate the effect of IPL therapy in patients with MGD on dry eye&#xD;
      parameters as well as subjective complaints.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 20, 2021</start_date>
  <completion_date type="Anticipated">November 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">October 20, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Bilateral comparison</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Difference Meibum quality score and expressibility between both eyes during the 6-month visit</measure>
    <time_frame>6-months visit</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Comparison of dry eye related parameters between both eyes (tear film break up time, Oxford Staining)</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of dry eye related parameters during the study period in the study eye (tear film break up time, Oxford Staining)</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of Ocular Surface Disease Index (OSDI) score during the study period</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">38</enrollment>
  <condition>Meibomian Gland Dysfunction</condition>
  <arm_group>
    <arm_group_label>Study eyes</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Study eye receives the standard energy dose as recommended by the manufacturer (between 8 and 12J/cm2, in accordance with the manufacturer's recommendations).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control eyes</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>The control eye is treated using low energy dose energy (1J/ cm2) as sham treatment, ensuring blinding of the respective patient.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Intense Pulsed Light therapy</intervention_name>
    <description>The LacryStim System is a CE marked device for treatment of meibomian gland dysfunction. It stimulates and reactivates meibomian glands and improves the related dry eye condition. Intense pulsed light is emitted with a light spectrum from 610nm to 1200nm. Each treatment consists of short individual pulses lasting for 4ms separated by a 26ms lasting interval to hinder tissue temperature increase, thermal damage to the skin and inflammatory reaction. During this phase 8 to 12 J / cm2 are delivered. Selection of total energy levels depends on the skin type (Fitzpatrick Skin Types) as recommended by the manufacturer.</description>
    <arm_group_label>Study eyes</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Sham Treatment</intervention_name>
    <description>The fellow eye serves as the control eye. Study eye receives the standard energy dose as recommended by the manufacturer (between 8 and 12J/cm2, in accordance with the manufacturer's recommendations). The control eye is treated using low energy dose energy (1J/ cm2) as sham treatment, ensuring blinding of the respective patient.</description>
    <arm_group_label>Control eyes</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age older than 18 years&#xD;
&#xD;
          -  Presence of meibomian gland dysfunction at any stage&#xD;
&#xD;
          -  Presence of meibomian glands on each lower eyelid's Meibography&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Fitzpatrick Skin Type VI&#xD;
&#xD;
          -  Usage of eye drops other than lubricants (e.g. antibiotics, steroids, cyclosporin-A)&#xD;
&#xD;
          -  Usage of systemic antibiotic therapy&#xD;
&#xD;
          -  Any pathology of the ocular surface except dry eye disease (e.g. corneal scarring,&#xD;
             cornea ectasia)&#xD;
&#xD;
          -  Ocular surgery within prior 3 months&#xD;
&#xD;
          -  Ocular injury within prior 3 months&#xD;
&#xD;
          -  Ocular herpes of eye or eyelid within prior 3 months&#xD;
&#xD;
          -  Active ocular infection&#xD;
&#xD;
          -  Active ocular inflammation or history of chronic, recurrent ocular inflammation within&#xD;
             prior 3 months&#xD;
&#xD;
          -  Eyelid abnormalities that affect lid function&#xD;
&#xD;
          -  Ocular surface abnormality that may compromise corneal integrity&#xD;
&#xD;
          -  Pregnancy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Stefan Palkovits, MD, PhD</last_name>
    <phone>+43 (0)1 91021- 57564</phone>
    <email>office@viros.at</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Andreas Schlatter, MD</last_name>
    <phone>+43 (0)1 91021- 57564</phone>
    <email>office@viros.at</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Vienna Institute for Research in Ocular Surgery</name>
      <address>
        <city>Vienna</city>
        <zip>1140</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Oliver Findl, MD, FEBO</last_name>
      <phone>+43 (0)1 91021- 57564</phone>
      <email>office@viros.at</email>
    </contact>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 20, 2021</study_first_submitted>
  <study_first_submitted_qc>October 20, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 22, 2021</study_first_posted>
  <last_update_submitted>October 20, 2021</last_update_submitted>
  <last_update_submitted_qc>October 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Vienna Institute for Research in Ocular Surgery</investigator_affiliation>
    <investigator_full_name>Prim. Prof. Dr. Oliver Findl, MBA</investigator_full_name>
    <investigator_title>Prim. Univ. Prof. Dr. Oliver Findl, MBA</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Meibomian Gland Dysfunction</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

